selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker to safely achieve patient plasma levels suitable for high target engagement Excellent safety and tolerability consistent with prior clinical experience; no dose-limiting toxicities and no serious safety […]